0000899243-20-028806.txt : 20201020
0000899243-20-028806.hdr.sgml : 20201020
20201020200444
ACCESSION NUMBER: 0000899243-20-028806
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201016
FILED AS OF DATE: 20201020
DATE AS OF CHANGE: 20201020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WILLIAMS DOUGLAS E
CENTRAL INDEX KEY: 0001184847
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39615
FILM NUMBER: 201249338
MAIL ADDRESS:
STREET 1: C/O AMGEN INC
STREET 2: ONE AMGEN CENTER DR
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320-1799
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Codiak BioSciences, Inc.
CENTRAL INDEX KEY: 0001659352
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ARCH VENTURE PARTNERS
STREET 2: 999 THIRD AVENUE, SUITE 3400
CITY: SEATTLE
STATE: WA
ZIP: 98104
BUSINESS PHONE: 857-400-4222
MAIL ADDRESS:
STREET 1: C/O ARCH VENTURE PARTNERS
STREET 2: 999 THIRD AVENUE, SUITE 3400
CITY: SEATTLE
STATE: WA
ZIP: 98104
FORMER COMPANY:
FORMER CONFORMED NAME: Codiak Biosciences, Inc.
DATE OF NAME CHANGE: 20151125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-16
0
0001659352
Codiak BioSciences, Inc.
CDAK
0001184847
WILLIAMS DOUGLAS E
C/O CODIAK BIOSCIENCES, INC.
35 CAMBRIDGEPARK DRIVE, SUITE 500
CAMBRIDGE
MA
02140
1
1
0
0
President & CEO
Common Stock
2020-10-16
4
C
0
9585
A
9585
D
Series C Preferred Stock
2020-10-16
4
C
0
66004
D
Common Stock
9585
0
D
Each share of Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-6.8855 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.
/s/ Yalonda Howze by Power of Attorney for Douglas E. Williams
2020-10-20